Signals, Powered By EquityPandit
The US health regulator has completed inspection of Lupin’s Nagpur facility, without making any observation.
The company in a BSE filing, “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection was concluded without any observations”. Moreover, its Nagpur facility manufactures oral solid products.
